Published: 18 October 2024
PMID: 39422825 DOI: 10.1007/s10815-024-03296-2
Alyssa Hochberg1,2, Michael H Dahan3, Hakan Yaral4,5, Lan N Vuong6,7,8, Sandro C Esteves9
Authors information
1 Department of Obstetrics and Gynecology, McGill University, 845 Rue Sherbrooke, O, Montreal, QC, 3HA 0G4, Canada. alyssahoch@gmail.com.
2 The Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. alyssahoch@gmail.com.
3 Department of Obstetrics and Gynecology, McGill University, 845 Rue Sherbrooke, O, Montreal, QC, 3HA 0G4, Canada.
4 Anatolia IVF, Ankara, Turkey.
5 Department of Obstetrics and Gynecology, Hacettepe University, Ankara, Turkey.
6 Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
7 IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.
8 HOPE Research Center, My Duc Hospital, Ho Chi Minh City, Vietnam.
9 ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil.
Abstract
Purpose: The purpose of this study is to investigate the impact of daily follicle-stimulating-hormone (FSH) dose on the likelihood of suboptimal response to ovarian stimulation (OS) for in vitro fertilization (IVF) according to POSEIDON’s criteria.
Methods: A tri-center retrospective cohort study (2015-2017) including women with normal anti-Müllerian hormone (AMH ≥ 1.2 ng/mL) and antral follicle count (AFC ≥ 5) values per POSEIDON’s criteria, undergoing their first IVF/ICSI cycle using conventional OS (FSH ≥ 150 IU/day). Suboptimal response was the retrieval of 4-9 oocytes. In previous research, we detected an AMH ≤ 2.97 ng/mL and AFC ≤ 12 as the optimal cut-offs predicting suboptimal response. Therefore, we examined the effect of daily FSH dose (≤ 300 IU versus > 300 IU) on suboptimal response risk for each AMH and AFC value within these thresholds (AMH between 1.20 and 2.97 ng/mL, by 0.01 ng/mL increments; and an AFC between 5 and 12, by unit increments). Analysis involved contingency tables and multivariable logistic regression.
Results: Included were 4005 patients with AMH and AFC values in the specific range, among whom 2131 (53.2%) were suboptimal responders. Among 177 AMH groups analyzed, apart from three distributed irregularly, daily FSH doses > 300 IU versus lower doses (≤ 300 IU) did not decrease suboptimal response risk; similarly, higher doses did not decrease risk at the eight AFC values examined (p > 0.05 for all). Using multivariable logistic regression, FSH doses were not associated with suboptimal response risk. Conversely, female age, AMH, AFC, and gonadotropin type were associated with suboptimal response.
Conclusions: In women with AMH values between 1.20 and 2.97 ng/mL and/or AFC between 5 and 12, FSH dose increase did not decrease suboptimal response risk. Individualizing the gonadotropin regimen and considering LH activity supplementation to FSH may mitigate risks.
Keywords: Follicle-stimulating hormone dose; Oocyte yield; POSEIDON criteria; Suboptimal ovarian response.